Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Pharmaceuticals, Inc. : Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

05/04/2012 | 04:05pm US/Eastern

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com. The webcast can also be accessed at the following URL: http://www.veracast.com/webcasts/baml/healthcare2012/id16635640.cfm

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

    CONTACTS:                         Investors:
                                      Lisa DeFrancesco
                                      (862) 261-7152

                                      Media:
                                      Charlie Mayr
                                      (862) 261-8030

(Photo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

SOURCE Watson Pharmaceuticals, Inc.

React to this article
Latest news on ACTAVIS INC
09:56aDJActavis Launches $21 Billion Bond Sale
09:38aDJU.S. Government Bonds Fall, as Corporate Sales Compete
08:27aDJActavis Lowers Yields On Megabond Sale
05:26a ASTRAZENECA : Acquisition of Rights to Actavis' Portfolio
02:46aDJASTRAZENECA : Completes Acquisition of Rights to Actavis' Portfolio
02:21aDJAstraZeneca PLC Acquisition of Rights to Actavis' Portfolio
03/02 ACTAVIS : and Medicines360 get FDA approval for pregnancy prevention drug Lilett..
03/02 ACTAVIS : Entry into a Material Definitive Agreement, Material Modification to R..
03/02DJActavis to Wrap Up Mega-Bond Sale on Tuesday
03/02 ACTAVIS : Announces Closing of Public Offerings of Ordinary Shares and Mandatory..
Dynamic quotes  
ON
| OFF